STEPHEN ROGERS: Open Payments
NPI 1609879675 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,434 in 80 payments from 19 companies in 2025. Trend: 2023 $813 · 2024 $820 · 2025 $1,434
Food & beverage: $1,434
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $338 |
| Bayer Healthcare Pharmaceuticals Inc. | 15 | $212 |
| AstraZeneca Pharmaceuticals LP | 6 | $167 |
| Braeburn Inc. | 10 | $164 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Amgen Inc. | 3 | $52 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
Products named: Kerendia, VRAYLAR, BRIXADI, BREZTRI, CAPLYTA, FANAPT, AIRSUPRA, REXULTI.
Industry payments across IN — which companies pay providers there.
